Would an unfavorable molecular subtype cause you to proceed with ALNDx after a positive SLNBx?
In a patient with a positive SLNBx, would triple negative or Her2+ status affect your decision on whether or not to proceed with a full ALNDx?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Allegheny Health Network, Pittsburgh
Answered on
I dont think we have data to suggest ALND is required in unfavorable subtypes with positive SLN if meeting up front criteria of Z011/AMAROS. Roughly 15% of Z011 were ER- and 300 of the roughly 1400 in AMAROS did not receive endocrine therapy so likely there were some unfavorable in these studies.
W...
Join for free or sign in to see the full answer